These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32222082)

  • 1. Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events.
    Jiang YK; Wang RY; Wang X; Zhao HZ; Zhou LH; Huang LP; Yip CW; Cheng JH; Que CX; Jiang C; Zhu LP
    Mycoses; 2020 Jun; 63(6):579-587. PubMed ID: 32222082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
    Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y
    Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.
    Kato H; Shiraishi C; Hagihara M; Mikamo H; Iwamoto T
    Sci Rep; 2024 May; 14(1):12519. PubMed ID: 38822123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole-associated visual disturbances and hallucinations.
    Bayhan GI; Garipardic M; Karaman K; Akbayram S
    Cutan Ocul Toxicol; 2016 Mar; 35(1):80-2. PubMed ID: 25799212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
    Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
    Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
    Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
    Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
    Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
    J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.
    He HR; Sun JY; Ren XD; Wang TT; Zhai YJ; Chen SY; Dong YL; Lu J
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):811-9. PubMed ID: 25515945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels.
    Xiong WH; Brown RL; Reed B; Burke NS; Duvoisin RM; Morgans CW
    Invest Ophthalmol Vis Sci; 2015 Feb; 56(2):1367-73. PubMed ID: 25650413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
    Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
    Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
    Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
    J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.